GDF-11

A TGF-beta superfamily protein almost identical to myostatin in its signaling domain, famous for parabiosis-era rejuvenation claims that later work either failed to reproduce or traced to antibody cross-reactivity.

Also referenced as: GDF11, Growth differentiation factor 11, BMP-11, BMP11, Bone morphogenetic protein 11, rGDF11

Also appears in: Anti-aging · Performance

COA Public product evidence No certificate records are bound to a tracked GDF-11 product page A record counts here only when a vendor publishes a certificate against one of its own tracked GDF-11 product pages. Other certificates naming this compound may still exist — search the wider certificate database. →

---

What is GDF-11?

GDF-11 is a protein, not a short peptide. Growth/differentiation factor 11 — also catalogued as bone morphogenetic protein 11, or BMP-11 — is a member of the transforming growth factor beta superfamily. It is made as a 407-amino-acid precursor (UniProt O95390) in three parts: a 24-residue signal peptide, a prodomain spanning residues 25 to 298 that is cut away by furin, and the 109-residue mature chain at residues 299 to 407, which pairs with a second copy through an interchain disulfide bond. The active molecule is therefore a homodimer of roughly 25 kDa, an order of magnitude heavier than the 5-to-40-residue synthetic chains sold alongside it in research-compound catalogs, with protein-scale requirements for expression, folding, and storage.

Its most important structural fact is also the source of most of the confusion around it: GDF-11 and GDF-8 — better known as myostatin, the growth factor that restrains skeletal muscle mass — share about 89% of their protein sequence, and the mature signaling domains are closer still. The two are close enough that antibodies raised against one frequently detect the other, and close enough that they activate the same intracellular pathway.

GDF-11 entered wide circulation because of a specific claim made between 2013 and 2014: that it is a youth factor present in young blood, that it declines with age, and that restoring it rejuvenates heart, muscle, and brain in old mice. That claim was challenged within two years and has never been settled. Recombinant GDF-11 is sold as a life-science reagent and appears in research-market listings on the strength of the rejuvenation story rather than on any human result.

How it works

• Canonical activin-receptor signaling. The mature dimer binds the type II receptors ActRIIA and ActRIIB and recruits the type I receptors ALK4, ALK5, and ALK7, triggering phosphorylation of SMAD2 and SMAD3. GDF-11 is the more potent SMAD2/3 activator of the two homologs and signals more effectively through those type I receptors than GDF-8; crystal structures of apo-GDF-8, apo-GDF-11, and GDF-11 bound to follistatin 288 localize the difference to the type I receptor binding site, though the authors noted that the biological consequences of that difference remained to be determined (Walker et al., BMC Biology, 2017;15(1):19).
• Latency controlled by the prodomain. Like myostatin, mature GDF-11 stays bound to its own prodomain after furin cleavage and remains inactive until BMP-1/tolloid metalloproteinases cut the prodomain again (Walker et al., Circulation Research, 2016;118(7):1125–1141). How much circulating GDF-11 is in the active form, rather than latent, is one reason serum measurements have been so difficult to interpret.
• The same downstream program as myostatin, including muscle atrophy. Side-by-side myoblast assays found GDF-11 and myostatin similar in activity and potency at activating phospho-SMAD2/3 and comparable in the degree of myotube atrophy they induce (Hammers et al., EMBO Molecular Medicine, 2017;9(4):531–544). Independent work reached the same conclusion, reporting that both proteins induce SMAD2/3 phosphorylation, inhibit myoblast differentiation, and regulate identical downstream signaling (Egerman et al., Cell Metabolism, 2015;22(1):164–174). Shared signaling is the mechanistic problem with calling GDF-11 pro-regenerative while calling myostatin anti-regenerative.
• Developmental patterning, not muscle growth, is its established role. Mice carrying a targeted deletion of Gdf11 show anteriorly directed homeotic transformations throughout the axial skeleton and posterior displacement of the hindlimbs, in a dose-dependent manner (McPherron et al., Nature Genetics, 1999;22(3):260–264). The gene’s non-negotiable function is anterior/posterior patterning during embryogenesis.
• Cardiac SMAD activation that reduces heart mass. Administering GDF-11 to mice rapidly activated myocardial SMAD2 and SMAD3 and decreased cardiac mass dose-dependently in both 2-month-old and 22-month-old animals after only nine days (Poggioli et al., Circulation Research, 2016;118(1):29–37). Whether a drop in cardiac mass is reversal of pathological hypertrophy or the beginning of cardiac atrophy is precisely what the field disagrees about.

Research status

The rejuvenation claims. Three papers from overlapping Harvard groups built the case. Heterochronic parabiosis regressed cardiac hypertrophy in old mice, and aptamer-based proteomics identified GDF11 as a circulating factor that declines with age; restoring it to youthful levels reversed age-related hypertrophy (Loffredo et al., Cell, 2013;153(4):828–839). Systemic GDF11 delivery then restored function and genomic integrity in aged satellite cells and increased strength and endurance capacity (Sinha et al., Science, 2014;344(6184):649–652), and young systemic factors including GDF11 improved cerebral vasculature and enhanced neurogenesis in aging mice (Katsimpardi et al., Science, 2014;344(6184):630–634).

The direct challenge. A group at the Novartis Institutes for Biomedical Research reported that these recent claims are not reproducible and that the reagents previously used to detect GDF11 are not GDF11 specific. Using a GDF11-specific immunoassay they found a trend toward increased GDF11 in sera of aged rats and humans and rising GDF11 mRNA in aging rat muscle, and they found that GDF11 significantly inhibited muscle regeneration and decreased satellite cell expansion in mice, the opposite sign of the Sinha result (Egerman et al., Cell Metabolism, 2015;22(1):164–174). The commentary published alongside it was blunt about the earlier case, under the title “GDF11 and the Mythical Fountain of Youth” (Brun and Rudnicki, Cell Metabolism, 2015;22(1):54–56).

The cardiac replication failure. Twenty-four-month-old C57BL/6 mice given recombinant GDF11 at 0.1 mg/kg daily for 28 days showed confirmed elevations in circulating rGDF11 but no significant effect on heart weight, body weight, ejection fraction, internal ventricular dimension, septal wall thickness, or myocyte cross-sectional area. The same work found no age-related pathological hypertrophy to rescue in disease-free old mice, and in vitro GDF11 did not reduce neonatal rat ventricular myocyte hypertrophy but induced it (Smith et al., Circulation Research, 2015;117(11):926–932).

The measurement dispute, unresolved. The original authors attributed Egerman’s age-related increase to cross-reactivity of the anti-GDF11 antibody with immunoglobulin, which itself rises with age, and reaffirmed a decline across mice, rats, horses, and sheep (Poggioli et al., Circulation Research, 2016;118(1):29–37; a correction to that paper was published in Circulation Research 2018;122(1):e3–e4). An independent LC-MS/MS assay built to resolve GDF11 from myostatin by unique sequence features then found that myostatin, but not GDF11, declines in healthy men throughout aging, with neither differing by age in healthy women, which places the age-related decline on myostatin rather than on the protein the earlier antibody work named. In a separate cohort with severe aortic stenosis, higher GDF11 tracked with frailty, diabetes, and prior cardiac conditions, and higher GDF11 at surgical baseline was associated with rehospitalization and adverse events after valve replacement (Schafer et al., Cell Metabolism, 2016;23(6):1207–1215). Because GDF-11 and myostatin are so close in sequence, nearly every antibody-based number published before these assays existed is ambiguous as to which protein it measured.

Cardiovascular and vascular work remains mixed. In humans, higher plasma GDF11/8 among 928 patients with stable ischemic heart disease was associated with a lower adjusted risk of the composite of heart failure hospitalization, stroke, myocardial infarction, and death (hazard ratio 0.45; 95% CI 0.33–0.60), replicated in 971 HUNT3 participants (adjusted HR 0.34; 95% CI 0.23–0.51), with less left ventricular hypertrophy at higher levels (Olson et al., European Heart Journal, 2015;36(48):3426–3434), an association study using an assay that does not separate GDF11 from GDF8, not a trial. In animals, targeted myocardial GDF11 gene delivery rejuvenated the aged mouse heart and enhanced myocardial regeneration after ischemia–reperfusion injury (Du et al., Basic Research in Cardiology, 2017;112(1):7), and GDF11 has been reported to alleviate oxidative-stress-induced senescence in endothelial progenitor cells by activating autophagy (Tao et al., Stem Cell Research & Therapy, 2024;15(1):370). Those positive signals coexist with the cardiac replication failure above and with the atrophy data below.

A clear safety signal at high exposure. AAV-mediated systemic overexpression of GDF11 in C57BL/6 mice produced substantial atrophy of skeletal and cardiac muscle and a cachexic phenotype not seen in mice expressing similar levels of myostatin; the authors concluded that GDF11 should be viewed as a potential deleterious biomarker in muscle wasting diseases rather than a therapeutic agent (Hammers et al., EMBO Molecular Medicine, 2017;9(4):531–544). A separate group found that elevated GDF11 caused reduced food intake, body weight, and muscle mass in mice, raised plasma activin A, and increased plasma GDF15 through SMAD2/3 recruitment to the GDF15 promoter; a GDF15-neutralizing antibody restored appetite but not muscle mass, which required blockade of ActRII signaling (Jones et al., Cell Reports, 2018;22(6):1522–1530).

No human trials of the protein. As of November 2026, a ClinicalTrials.gov search for growth differentiation factor 11 returns no study that administers recombinant GDF11 (the records that mention it use it as a blood biomarker in aging, exercise, and surgical cohorts), and no registered study lists Elevian, the company founded around the parabiosis work, as a sponsor. There is no published human pharmacokinetic, safety, or efficacy data for the protein, and no regulatory authority has approved it for anything.

One registry entry invites a misreading. A phase 3 trial of an injectable agent abbreviated “GD-11” in acute ischemic stroke is registered in China (NCT06299579, Beijing Tiantan Hospital, 980 planned participants, start date February 29, 2024). Its phase 2 report describes GD-11 as a brain cytoprotective drug designed to cross the blood–brain barrier via the glucose transporter; across 15 Chinese sites and 239 patients randomized between November 17, 2022 and March 22, 2023, the proportion with a modified Rankin Scale score of 0–1 at 90 days was 77.5% on the higher dose, 72.2% on the lower, and 67.5% on placebo, a difference that was not statistically significant (p=0.3671) (Zhang et al., Stroke and Vascular Neurology, 2025;10(2):e003338). That agent is not recombinant GDF11, and the trial is not evidence about this protein.

Common dosage forms

• Lyophilized recombinant protein in biochemical-reagent vials. Microgram fills, with milligram quantities handled as custom orders, supplied carrier-free or with a carrier protein such as bovine serum albumin and labeled for laboratory research use only. Handling is by laboratory personnel; there is no clinical presentation and no prescriber.
• Mammalian-cell-expressed, insect-cell-expressed, and E. coli-expressed versions. All are catalogued, and they are not interchangeable: a dimeric TGF-beta superfamily protein requires correct disulfide pairing, and bacterial constructs frequently carry an added N-terminal methionine or a polyhistidine purification tag.
• Mature-domain protein and latent prodomain complex. Both appear in catalogs, sometimes under the same short name. Because the prodomain holds the mature dimer inactive until BMP-1/tolloid cleavage, these two items have different biological activity despite near-identical labeling.
• No approved drug product, compounded preparation, pen, or oral form exists. Nothing in the pharmacy or clinical supply chain corresponds to GDF-11, and a 25 kDa disulfide-linked protein dimer would not survive oral administration.

Key considerations

• Regulatory status. The Research Market status reflects the absence of any US approval and of any registered human clinical development, alongside sale by research-reagent and research-compound suppliers. Where it is sold on a longevity or muscle-building promise, the published record points the other way.
• A protein, not a peptide. A 109-residue chain that must dimerize and fold correctly to be active has protein-scale requirements for expression, handling and characterization that short synthetic peptides do not, and its near-identity to myostatin makes identity confirmation harder still.
• The foundational evidence is contested in both directions, and the measurement problem is the core of it. The direction of GDF-11’s change with age, whether it helps or harms muscle regeneration, and whether it reverses or induces cardiac hypertrophy have each been reported both ways by competent groups, and much of the pre-2016 literature rests on antibodies that cannot distinguish GDF-11 from myostatin.
• The strongest safety signal points toward wasting, not rejuvenation. Supraphysiological GDF-11 in mice produced skeletal and cardiac muscle atrophy and cachexia, no dose-ranging or exposure-response work in humans exists to define where a safe range might begin, and the protein’s embryonic patterning role gives separate reason for caution about systemic exposure.
• Several names collide here. GDF-11 and BMP-11 are the same protein. GDF-8 is myostatin, a different protein with opposite marketing but overlapping biology, and myostatin propeptide is an inhibitor on that pathway. GDF-15 is an unrelated anorectic factor that GDF-11 induces, and ActRII-targeting biologics such as luspatercept bind GDF-11 among several ligands but are not GDF-11 either.